NasdaqGS:RXRXBiotechs
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades
Recursion Pharmaceuticals (RXRX) just put fresh clinical data on the table, and that is what has traders paying attention. The new TUPELO trial update for REC-4881 in familial adenomatous polyposis could reshape expectations around this AI driven pipeline.
See our latest analysis for Recursion Pharmaceuticals.
Even with the upbeat TUPELO data and a wave of bullish commentary on its AI driven platform, Recursion’s 1 month share price return of 6.7% comes against a much weaker year to date...